RxDoctor Payments Data

Rodolfo Tabila, MD

Family Medicine · Long Beach, CANPI 1962538181

Payments from drug & device makers

$12,517in general payments, 2019–2025

Across 562 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$1K
  • GSK$1K
  • Amarin Pharma, Inc.$1K
  • Novo Nordisk$931
  • Pfizer$812
  • plus $6K from 34 others

What the payments were for

  • Food & beverage$12,491100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,517 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$35,642
Medicare patients
139
Services billed
304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin83$81,390
VascepaIcosapent Ethyl111$58,473
EliquisApixaban59$54,258
RybelsusSemaglutide45$53,881
FarxigaDapagliflozin Propanediol64$53,785
OzempicSemaglutide33$43,166
XareltoRivaroxaban31$32,185
Icosapent Ethyl100$26,474
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$26,122
JanuviaSitagliptin Phosphate21$24,684
TrulicityDulaglutide16$21,534
LinzessLinaclotide30$19,332
Alcohol Prep PadsAlcohol Antiseptic Pads123$10,542
Bydureon BciseExenatide Microspheres13$10,473
KerendiaFinerenone12$8,694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$931$97,04778 claims
Boehringer IngelheimJardiance, Spiriva Respimat$661$88,13496 claims
PfizerEliquis$812$54,25859 claims
AstraZenecaFarxiga$1,768$53,78564 claims
GSKTrelegy Ellipta, Breo Ellipta$1,154$33,68451 claims
Johnson & JohnsonXarelto$318$32,18531 claims
MerckJanuvia$249$24,68421 claims
Lilly USA, LLCTrulicity$639$21,53416 claims
AbbVieLinzess$125$19,33230 claims
BayerKerendia$801$8,69412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →